| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Laboratoire Jean-Claude Heuson de Cancérologie Mammaire, Institut Jules Bordet, Université Libre de Bruxelles, 127 boulevard de Waterloo, B-1000 Bruxelles, Brussels, Belgium
(Requests for offprints should be addressed to M Lacroix; Email: Marc.Lacroix{at}ulb.ac.be)
It is widely believed that ductal breast cancer dissemination involves a succession of clinical and pathological stages starting with carcinoma in situ, progressing into invasive lesion and culminating in metastatic disease. Such changes have frequently been attributed to the sequential acquisition of various alterations in a single cell followed by clonal selection and expansion, thus leading to intra-tumor diversity. According to this multi-step view, extensive genotype and phenotype (marker expression, grade) shift may occur in the same tumor during progression; this may lead to the coexistence of molecularly and/or pathologically different areas within the same lesion. An increasing amount of data of various natures now appear to challenge this concept: only a few distinct ‘portraits’, in relation to estrogen receptor (ER) status and grade, may be found among tumors. Moreover, although undergoing increasing genetic alteration, most individual lesions largely maintain their phenotype when they evolve from in situ to the metastatic state. While many of the data presented here are related to ductal tumors, lobular cancer is also discussed.
This article has been cited by other articles:
|
|
 |
|
  P. Simpson Linear and Nonlinear Models of Progression from In situ to Invasive Breast Cancer Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 105 - 109. [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Slanger, J. C. Chang-Claude, N. Obi, S. Kropp, J. Berger, E. Vettorazzi, W. Braendle, G. Bastert, S. Hentschel, and D. Flesch-Janys Menopausal Hormone Therapy and Risk of Clinical Breast Cancer Subtypes Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1188 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Harrell, W. W. Dye, D. M.E. Harvell, M. Pinto, P. Jedlicka, C. A. Sartorius, and K. B. Horwitz Estrogen Insensitivity in a Model of Estrogen Receptor Positive Breast Cancer Lymph Node Metastasis Cancer Res., November 1, 2007; 67(21): 10582 - 10591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Jakobsen, N. Rasmussen, A.-V. Laenkholm, and H. J. Ditzel Phage Display Derived Human Monoclonal Antibodies Isolated by Binding to the Surface of Live Primary Breast Cancer Cells Recognize GRP78 Cancer Res., October 1, 2007; 67(19): 9507 - 9517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Bertagnolo, M. Benedusi, F. Brugnoli, P. Lanuti, M. Marchisio, P. Querzoli, and S. Capitani Phospholipase C-{beta}2 promotes mitosis and migration of human breast cancer-derived cells Carcinogenesis, August 1, 2007; 28(8): 1638 - 1645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Heldring, A. Pike, S. Andersson, J. Matthews, G. Cheng, J. Hartman, M. Tujague, A. Strom, E. Treuter, M. Warner, et al. Estrogen Receptors: How Do They Signal and What Are Their Targets Physiol Rev, July 1, 2007; 87(3): 905 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.-A. Toillon, C. Lagadec, A. Page, V. Chopin, P.-E. Sautiere, J.-M. Ricort, J. Lemoine, M. Zhang, H. Hondermarck, and X. Le Bourhis Proteomics Demonstration That Normal Breast Epithelial Cells Can Induce Apoptosis of Breast Cancer Cells through Insulin-like Growth Factor-binding Protein-3 and Maspin Mol. Cell. Proteomics, July 1, 2007; 6(7): 1239 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. R. Yang, M. E. Sherman, D. L. Rimm, J. Lissowska, L. A. Brinton, B. Peplonska, S. M. Hewitt, W. F. Anderson, N. Szeszenia-Dabrowska, A. Bardin-Mikolajczak, et al. Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 439 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Steinman, J. Wang, P. Bourne, Q. Yang, and P. Tang Expression of Cytokeratin Markers, ER-alpha, PR, HER-2/neu, and EGFR in Pure Ductal Carcinoma In Situ (DCIS) and DCIS with Co-existing Invasive Ductal Carcinoma (IDC) of the Breast Ann. Clin. Lab. Sci., January 1, 2007; 37(2): 127 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tang, X. Wang, L. Schiffhauer, J. Wang, P. Bourne, Q. Yang, A. Quinn, and S. I. Hajdu Relationship between Nuclear Grade of Ductal Carcinoma in situ and Cell Origin Markers. Ann. Clin. Lab. Sci., December 1, 2006; 36(1): 16 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lacroix Significance, detection and markers of disseminated breast cancer cells Endocr. Relat. Cancer, December 1, 2006; 13(4): 1033 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Ivshina, J. George, O. Senko, B. Mow, T. C. Putti, J. Smeds, T. Lindahl, Y. Pawitan, P. Hall, H. Nordgren, et al. Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer Cancer Res., November 1, 2006; 66(21): 10292 - 10301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Cornett, J. A. Mobley, E. C. Dias, M. Andersson, C. L. Arteaga, M. E. Sanders, and R. M. Caprioli A Novel Histology-directed Strategy for MALDI-MS Tissue Profiling That Improves Throughput and Cellular Specificity in Human Breast Cancer Mol. Cell. Proteomics, October 1, 2006; 5(10): 1975 - 1983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Eeckhoute, J. S. Carroll, T. R. Geistlinger, M. I. Torres-Arzayus, and M. Brown A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer Genes & Dev., September 15, 2006; 20(18): 2513 - 2526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. F. Anderson and R. Matsuno Breast cancer heterogeneity: a mixture of at least two main types? J Natl Cancer Inst, July 19, 2006; 98(14): 948 - 951. [Full Text] [PDF]
|
|
|
|
|
|
M. Lacroix, R.-A. Toillon, and G. Leclercq p53 and breast cancer, an update. Endocr. Relat. Cancer, June 1, 2006; 13(2): 293 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Capurso, S Lattimore, T Crnogorac-Jurcevic, F Panzuto, M Milione, V Bhakta, N Campanini, S M Swift, C Bordi, G D. Fave, et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr. Relat. Cancer, June 1, 2006; 13(2): 541 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Revillion, M. Charlier, V. Lhotellier, L. Hornez, S. Giard, M.-C. Baranzelli, J. Djiane, and J.-P. Peyrat Messenger RNA expression of leptin and leptin receptors and their prognostic value in 322 human primary breast cancers. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2088 - 2094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tang, X. Wang, L. Schiffhauer, J. Wang, P. Bourne, Q. Yang, A. Quinn, and S. Hajdu Expression Patterns of ER-{alpha}, PR, HER-2/neu, and EGFR in Different Cell Origin Subtypes of High Grade and Non-High Grade Ductal Carcinoma In Situ. Ann. Clin. Lab. Sci., March 1, 2006; 36(2): 137 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Shen, Y. Yang, L. Y. T. Inoue, M. F. Munsell, A. B. Miller, and D. A. Berry Role of Detection Method in Predicting Breast Cancer Survival: Analysis of Randomized Screening Trials J Natl Cancer Inst, August 17, 2005; 97(16): 1195 - 1203. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
